Study of an experimental drug for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed metastatic or unresectable solid tumor (cancer found on biopsy or scan tissue sample).
- Your cancer can be measured on imaging (it must meet specific measurement rules set by the study).
- You have tried and your cancer progressed after all standard treatments for advanced disease.
- Your energy/strength level is good enough (ECOG 0–1).
- Your organs and bone marrow work well enough for safe treatment (lab results must meet study targets).
- You do not have key reasons to be excluded, including certain genetic mutation types and serious heart or brain-related issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called VVD-133214, alone or with other medicines, in people with advanced solid tumors that have specific DNA repair problems (MSI-H/dMMR). The goal is to see if it is safe and effective.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This trial tests a new drug for people with advanced solid tumors that have spread or can't be removed. The drug targets specific proteins on cancer cells to try to shrink or slow the cancer.
This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.
This trial tests a new combination treatment (CVL006 plus other drugs) in people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if the combination can shrink tumors and help patients live longer.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.